On Monday, Shares of Apple Inc. (NASDAQ:AAPL), lost -2.36% to $118.44, after Apple Watch chip supplier partner fails to reach break-even volume in second quarter.
The blue-chip technology company’s stock closed 10.9% below the Feb. 23 record close of $133, and at the lowest since Jan. 30. Many view declines of up to 10% from a noteworthy peak a pullback, and declines of at least 10% to up to 20% a correction. A bear market is a drop of 20% or more. The last time the stock closed at least 10% below a noteworthy peak was Jan. 16, 2015. Apple’s stock also crossed below the closely-watched 200-day moving average, which many chart watchers use as a guide to a stock’s long-term trend. The last time it closed below the 200-day moving average Sept. 17, 2013. MarketWatch Reports
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of Denbury Resources Inc. (NYSE:DNR), declined -6.35% to $3.69, during its last trading session.
Denbury Resources will host a conference call to review and talk about second quarter 2015 financial and operating results on Wednesday, August 5, 2015 at 10:00 A.M. (Central).
Denbury Resources Inc. operates as an independent oil and natural gas company in the United States. The company primarily focuses on improved oil recovery utilizing carbon dioxide. It holds properties located in Mississippi, Texas, Louisiana, and Alabama in the Gulf Coast region; and in Montana, North Dakota, and Wyoming in the Rocky Mountain region.
Finally, Mylan N.V. (NASDAQ:MYL), ended its last trade with -1.41% loss, and closed at $55.20.
Mylan declared that it will hold its extraordinary general meeting of shareholders in connection with its projected acquisition of Perrigo Company plc (NYSE: PRGO; TASE) at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 at 1 p.m. Central European Time (CET).
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
